Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose AraC with Clofarabine in Elderly AML Patients Not Eligible for Conventional Chemotherapy
DRKS00000580Phase 2Terminated
- Sponsor
- Leipzig University
- Start
- Oct 2010
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of clofarabine and cytarabine in acute myeloid leukemia (AML), sponsored by Leipzig University. Primary endpoints: Safety, Complete remission rate and 1 more. Started Oct 2010; status: terminated.
02
Drugs
clofarabinecytarabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on DRKS00000580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00000580.